Mutations in the gene ANT1 may raise risk for bipolar disorder through a complex interplay between serotonin and mitochondrial signaling in the brain.
These two pathways have been separately implicated in bipolar disorder, but the link between levels of the neurotransmitter serotonin and mitochondrial dysfunction had not been established. Researchers at the RIKEN Center for Brain Science (CBS) in Japan now report that mitochondrial dysfunction affects the activity of serotonergic neurons in mice with mutations of ANT1.
Mitochondria are the vital organelles that deliver energy to all cells and mitochondrial damage has been found, for example, in brain imaging of bipolar patients and in post-mortem brains. Roughly 20 percent of patients with mitochondrial disease also have bipolar disorder, a major psychiatric disease characterized by manic and depressive episodes.
Altered serotonin functioning, on the other hand, seems to be involved in bipolar disorder because drugs that target serotonin levels can effectively treat the condition.
Tadafumi Kato, research group leader at CBS, said:
“Our study suggests that mitochondrial dysfunction can alter activity of serotonergic neurons in bipolar disorder, and this is the first time these two lines of evidence have been linked.”
The study started by identifying ANT1 mutations in patients with bipolar disorder. Kato and colleagues then looked at mice lacking the ANT1 gene in the brain only.
Compared with non-mutant mice, the mitochondria in these knockout mice could not retain calcium and had leakier pores. The ANT1-mutant mice also showed lower impulsivity in behavior tests, and consistent with this, their brains showed elevated serotonin turnover.
This hyper-serotonergic state is likely a result of a cascade of changes that starts with the loss of the ANT1 gene and the resulting dysfunctional mitochondria. Enhanced serotonergic activity may then further impair mitochondria in a vicious cycle.
Targeting Mitochondrial Dysfunction
Serotonergic neurons were found to deteriorate in a brain area called the dorsal raphe, which is a region also affected in Parkinson’s disease — another condition that may have its roots in mitochondrial dysfunction. The ANT1 mutation does not cause bipolar disorder, says Kato, but is associated with elevated risk.
The implication of this research is that emerging therapies for the underlying mitochondrial dysfunction could one day treat bipolar disorder more successfully than today’s variable serotonin-targeting drugs.
The study does have some limitations. The results in calcium retention capacity are inconsistent with earlier studies that showed a loss of Ant1 causing an increase in calcium retention capacity. Also, it is unclear why homozygous Ant1 cKO mice do not show behavioral alterations in some of the experiments.
The work was supported by a JSPS KAKENHI Grant, and the Advanced Genome Research and Bioinformatics Study to Facilitate Medical Innovation (GRIFIN) from the Japan Agency for Medical Research and Development.
Tomoaki M. Kato, Mie Kubota-Sakashita, Noriko Fujimori-Tonou, Fumihito Saitow, Satoshi Fuke, Akira Masuda, Shigeyoshi Itohara, Hidenori Suzuki & Tadafumi Kato
Ant1 mutant mice bridge the mitochondrial and serotonergic dysfunctions in bipolar disorder
Molecular Psychiatry (2018). DOI: 10.1038/s41380-018-0074-9
Top Image: Milena Menezes Carvalho/RIKEN National Science Institute